trial summary · NCT07430202
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
A Phase 1b Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab for Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
Source record: https://clinicaltrials.gov/study/NCT07430202
Facts
| registry id | NCT07430202 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) |
| sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| sponsor class | OTHER |
| enrollment | 27 |
| start date | 2026-10-28 |
| primary completion | 2030-10 |
| completion | 2030-10 |
| results posted | not reported |
Conditions
- Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Interventions
- DNAJB1-PRKACA Peptide Vaccine
- DRP-104
- Nivolumab
- Ipilimumab
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.